Genomate Health的动态

International Lung Cancer Awareness Day: Meet Our Experts Today, on International Lung Cancer Awareness Day, we recognize the ongoing battle against this disease and emphasize the importance of research, prevention, and advanced treatment. Leading the Lung Oncology Unit at the Sharett Oncology Institute is Professor Hovav Nechushtan, one of Israel's top physicians in his field. Professor Nechushtan has been ranked by Forbes magazine as one of the best doctors in Israel. About a year and a half ago, he was honored as one of the outstanding physicians in the "Medicine with a Soul: @Hadassah Medical Center’s Best Doctors" initiative. Professor Nechushtan: "In personalized medicine for lung cancer, we identify the unique characteristics of each tumor and patient, and tailor a targeted treatment accordingly." We appreciate Professor Nechushtan's contributions to clinical research and personalized medicine in lung cancer. #SharettOncologyInstitute #LungCancerAwarenessDay #FightAgainstCancer #PersonalizedMedicine #TopExperts

?? We are excited to announce a new gastroesophageal cancer trial, DECIPHER, that will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release below. #Natera #Signatera #CancerResearch https://ow.ly/Z1BE50SqRRA

September is not only #BloodCancerAwarenessMonth but also this week marks the conclusion of the ESMO - European Society for Medical Oncology conference in Barcelona, highlighting groundbreaking advancements in cancer treatment. ? This month is a time to recognise the incredible strides made in blood cancer therapies and to honour the dedicated professionals who work tirelessly in cancer care. ? A major breakthrough in 2024 was the FDA approval of blinatumomab, a bispecific T-cell engager for acute lymphoblastic leukaemia (ALL). This innovative therapy helps the immune system directly target and eliminate cancer cells in patients whose disease has relapsed, offering renewed hope for improved remission. ? Additionally, advancements in treatments like CAR T-cell therapies and other precision medicines continue to transform the landscape of cancer care, enhancing survival rates and reducing side effects. These strides in research are giving patients and their families more options than ever before, making a profound impact on the fight against blood cancers! ? #BloodCancerAwarenessMonth #LeukemiaResearch #OncologyInnovations #CancerTreatmentAdvances ? ?? Naz Saeed

?? A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/eAPARqRZ

The launch of a "world-first trial" that could change how we treat brain cancer in the UK, has been announced. Known as the 5G platform trial, it will test multiple new treatments for people living with an aggressive form of brain cancer called glioblastoma (GBM). It will use a unique and flexible approach to test multiple drugs, with each patient's treatment being based on the specific genetics of their cancer. Dr Juanita Lopez, the Chief Investigator of the trial said: “We have seen progress made in better treating many types of cancer in recent decades, but less so in brain cancers like glioblastoma." This trial uses an adaptive design and whole genome sequencing for every patient. The drug combinations given to patients can be changed as real-time data is collected, allowing researchers to try multiple treatment options across different groups of patients. This approach increases the likelihood of finding a treatment plan that works best for each patient. Find out more about this exciting new trial ?? https://bit.ly/40jl4XZ #BrainCancer #CancerResearch #Glioblastoma

ALLG has had over five decades of significant impact on blood cancer treatments, with our member doctors driving innovative clinical trial research in pursuit of our mission of better treatments and better lives for people with blood cancer. Our recently published compendium, ‘Five Decades of Impactful Published Research’, highlights ALLG’s groundbreaking blood cancer research over 50+ years and our role in generating high-quality evidence for new and better treatments for leukaemia, lymphoma, myeloma and other blood cancers. ? ALLG is the only not-for-profit, blood cancer clinical trial research group in Australia and New Zealand. Our members include over 1,400 haematologists and blood cancer experts, dedicated to investigator-initiated research that creates better treatments, better outcomes and better quality of life for patients. You can read more about ALLG’s 50 years of research at https://lnkd.in/g4bQp_HH. To support ALLG’s research, visit https://lnkd.in/g2TeJBa. #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials?? #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology?#haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

?? A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/gfmExRYc

Check out these six abstracts on lung cancer by Guardant Health which will be presented at the IASLC 2024 World Conference on Lung Cancer in San Diego, California, USA from September 7th to 10th, 2024. https://lnkd.in/gAksTcfz The 50th anniversary of the International Association for the Study of Lung Cancer (IASLC) marks half a century of remarkable achievements and progress in the field of lung cancer diagnosis and treatment with this year’s theme centred on exploring insights and innovations in lung cancer. https://lnkd.in/d-wkHerR Visit us at https://lnkd.in/dVEkKyRC to learn more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. These tests are for prescription use only. Speak to your doctor today about comprehensive genomic profiling. #guardanthealth #guardanthealthamea #WCLC24 #IASLC #liquidbiopsy #liquidissolid #lungcancer #NSCLC #abstracts #clinicalresearch #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #CGP #cancerpatients #medicaloncologists

Lung cancer is the leading cause of death around the world, and unfortunately, patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations face inevitable disease progression. ? ? Our priority at Johnson & Johnson Innovative Medicine is to challenge the current treatment landscape for these patients by developing unparalleled, personalized, targeted therapies for earlier intervention to create meaningful change.?? ? Luca Dezzani wrote an incredibly impactful article for @Endpoints News, detailing the immense need for additional therapies and our patient-centric approach to helping solve these problems.?? ? We believe lung cancer patients deserve better options for treatment. Learn more about how we plan to deliver at https://bit.ly/3xaoGiZ. #MyCompany #LungCancer #NSCLC #TargetedTherapy?

?? A new gastroesophageal cancer trial, DECIPHER, will utilize Natera's personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. “With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies,” said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. “Signatera’s personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study.” Read more in the press release. #Natera #Signatera #CancerResearch https://lnkd.in/gs2Ffgte